固态器官移植排斥反应市场（依排斥类型、捐赠方式、移植器官类型和最终用户划分）－2025-2032年全球预测

预计到 2032 年，固态器官移植排斥治疗市场将成长至 134.1 亿美元，复合年增长率为 5.50%。

了解固态器官移植排斥反应在临床、诊断和治疗方面不断演变的现状，以及整合式照护路径和创新方面的策略必要性。

固态器官移植仍然是现代医学中最具变革性的治疗方法之一，但排斥反应仍然是临床和运作中面临的核心挑战。随着手术效果的改善，人们的关注点已转向驱动急性、慢性及超急性排斥反应的各种免疫反应，每种反应都需要不同的诊断、监测和治疗方法。免疫学、诊断学和治疗学之间不断演变的相互作用，正迫使临床医生、医院系统、製造商和支付方重新评估治疗路径及其相关基础设施。

诊断、治疗、数位整合、监管重点和跨部门合作方面的变革性变化正在重塑移植排斥反应的检测和管理方式。

移植排斥反应的管理格局正经历多重并行变革，这些变革共同重塑治疗标准。其中一个关键变化是精准诊断技术的成熟。血液检测、先进的影像学检查和精密的组织切片检查技术正在融合，从而能够早期、特异性检测免疫介导的损伤。诊断技术的进步与免疫调节剂的改进相辅相成，包括改良的抗体疗法、标靶抗代谢药物、优化的Calcineurin酶抑制剂方案以及类固醇减量策略，这些都为更个人化的免疫抑制治疗创造了可能，从而降低排斥反应和长期毒性。

评估自 2025 年起生效的美国关税变化对移植医学的器官取得、製造地、国际合作和供应链韧性的影响。

预计2025年生效的美国关税将进一步加剧现有供应链的压力，并促使许多移植相关人员重新评估筹资策略。血液检测、诊断成像平台和组织切片检查处理中使用的设备和试剂通常依赖跨国供应链，而不断上涨的进口成本和复杂的海关程序正在影响采购决策、库存管理实践和供应商多元化。因此，一些移植中心和专科诊所正在加快关键库存在地化的步伐，协商签订多年供应商协议，并采用包含许多国内可用组件的替代技术。

整合排斥表型、诊断方法、治疗方法分类、器官特异性因素以及医疗环境影响等细分领域的指南，以指导策略优先排序。

要深入了解市场动态，需要检验构成移植排斥反应管理的关键细分领域。就排斥反应类型而言，急性排斥反应需要快速诊断确认和有效的免疫抑制治疗；慢性排斥反应需要长期监测和采取措施来减轻移植物的进行性劣化；而超急性排斥反应则需要即时进行手术全期识别和干预。因此，每种排斥反应表型都有其独特的临床重点和技术要求。

美洲、欧洲、中东和非洲以及亚太地区的区域模式和采用趋势将影响研究重点、临床整合以及移植创新成果的取得。

区域差异深刻影响移植排斥预防和管理创新技术的采纳和融入医疗保健系统的方式。在美洲，高容量的移植中心和完善的报销机制促进了先进诊断技术和新型治疗方法的快速应用，而区域间医疗资源分配的差异则需要重点关注如何扩大医疗服务能力并确保公平分配。在欧洲、中东和非洲，不同的法规结构和医疗体系模式导致了技术应用的不平衡。学术机构和国家级转诊医院主导临床研究和最佳实践的推广，而其他地区则专注于务实、资源高效的方案。

透过竞争与合作并存的公司洞察，揭示诊断创新者、治疗药物开发商和供应链策略家如何为临床和营运领导地位做好准备。

移植排斥反应管理领域的竞争格局呈现出成熟医疗公司与专业创新企业并存的局面，二者都在推动技术进步与临床应用。诊断公司正投资开发可扩展的平台，用于灵敏的血液检测和组织分析；影像供应商则专注于增强移植监测和功能评估的影像技术。製药和生物技术公司不断改进免疫抑制疗法，推进针对特定免疫路径的抗体和小分子药物研发项目，并经常与学术机构合作，以检验临床终点和安全性。

为高阶主管和临床领导者提供切实可行的建议，以加速诊断技术的普及应用、加强供应链、协调伙伴关係，并在医疗机构中扩大公平的医疗服务取得途径。

产业领导者应推动一系列合作，将科学进步转化为更长的移植器官寿命和可衡量的患者疗效改善。首先，优先投资于能够实现早期、非侵入性检测的诊断技术，将提高临床应对力，并减少对侵入性手术的依赖。其次，将「诊断-治疗演算法」纳入临床工作流程，并辅以可互通的医疗资讯科技、决策支援和临床医师培训，将加速这些演算法的推广应用，并提高各医院、移植中心和专科诊所之间诊疗服务的一致性。此外，各机构应促进策略联盟，将诊断设备製造商、药物研发商和研究机构联合起来，共同设计检验研究和真实世界证据项目，以证明这些技术在心臟、肾臟、肝臟、肺臟和胰臟移植中的临床效用。

采用透明的混合方法调查方法，结合同侪审查的证据、专家访谈和操作证据，得出可靠的实用结论。

本报告的分析采用了一种严谨的混合调查方法，旨在确保其可靠性、相关性和实用性。二级研究系统性地回顾了同侪审查的临床文献、监管申报文件和已发表的技术文件，以描述各种排斥表型的诊断技术、治疗机制和临床管理策略。此外，还开展了一级研究，对移植临床医生、实验室主任、器官获取负责人和行业高管进行了结构化访谈，以了解他们对未满足的需求、实施障碍和实际应用驱动因素的观点。

结论整合了临床和策略要务，旨在透过诊断、治疗、协作和强有力的实施策略来提高移植器官的长期存活率。

固态器官移植正处于一个十字路口，科学创新、临床实务和系统层面的考量在此交汇，共同影响着病患的预后。诊断和治疗方法的进步具有降低急性、慢性及超急性排斥反应发生率和影响的真正潜力。然而，要实现这一潜力，需要製造商、临床医生、医疗系统和政策制定者之间的协调行动。对非侵入性监测、实证医学、互通工作流程和稳健的供应链进行策略性投资，是把科学进步转化为常规临床效益的关键。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 开发供体特异性生物标记用于早期检测移植排斥反应
• 基于患者临床数据的机器学习演算法在排斥风险预测的应用
• 利用调节性T细胞疗法诱导固态器官移植受者免疫耐受
• 寻找新型共刺激抑制剂以预防急性移植排斥反应
• 非侵入性影像诊断技术的进步，用于全面监测移植后器官健康状况
• 为移植患者引入基于药物基因组学分析的个人化免疫抑制疗法
• 透过将人工智慧工具整合到移植免疫学研究中来优化长期移植存活率

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章固态器官移植排斥反应市场（依排斥反应类型划分）

• 急性排斥反应
• 慢性排斥
• 超急性排斥

第九章固态器官移植排斥反应市场（依产品/服务分类）

• 诊断和测试解决方案
  • 血液检查
  • 影像检查
  • 组织切片检查
• 药物
  • 抗体
  • 抗代谢物
  • Calcineurin抑制剂
  • 类固醇

第十章 依移植器官类型分類的固态器官移植排斥反应市场

• 心
• 肾
• 肝
• 肺
• 胰臟

第十一章固态器官移植排斥反应市场（依最终用户划分）

• 医院及移植中心
• 研究所
• 专科诊所

第十二章固态器官移植排斥反应市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章固态器官移植排斥反应市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国固态器官移植排斥反应市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Abbott Laboratories
  • Accord Healthcare Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Biocon
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eurofins Transplant Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Globela Pharma
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Natco Pharma Ltd.
  • Novartis AG
  • Panacea Biotec Pharma Ltd.
  • Pfizer Inc.
  • Plexision
  • Sanofi SA
  • Strides Pharma Global Pte Ltd.
  • Thermo Fisher Scientific Inc.
  • Veloxis Pharmaceuticals A/S
  • Zydus Lifesciences Limited

The Solid Organ Transplantation Rejection Market is projected to grow by USD 13.41 billion at a CAGR of 5.50% by 2032.

Introducing the evolving clinical, diagnostic, and therapeutic environment of solid organ transplant rejection and the strategic imperatives for integrated care pathways and innovation

Solid organ transplantation remains one of the most transformative interventions in modern medicine, yet rejection continues to be a central clinical and operational challenge. As surgical outcomes have improved, attention has shifted to the heterogenous immune responses that lead to acute, chronic, and hyperacute rejection, each of which demands distinct diagnostic, monitoring, and therapeutic approaches. The evolving interplay between immunology, diagnostics, and therapeutics requires clinicians, hospital systems, manufacturers, and payers to re-evaluate care pathways and the supporting infrastructure.

In recent years, advances in molecular diagnostics and noninvasive monitoring have opened new possibilities for earlier detection and individualized immunosuppression, while therapeutic innovations seek to balance efficacy with long-term safety. At the same time, differences in transplanted organs-such as the physiologic and immunologic nuances of heart, kidney, liver, lung, and pancreas transplantation-shape both clinical practice and product development. Consequently, stakeholders must synthesize evidence across rejection type, diagnostic and medication offerings, organ-specific considerations, and the diverse environments in which transplant care is delivered. This introduction sets the context for a focused examination of those elements and frames the priorities that will guide clinical effectiveness, patient outcomes, and system-level value creation.

Transformative shifts in diagnostics, therapeutics, digital integration, regulatory focus, and cross-sector collaboration that are reframing how transplant rejection is detected and managed

The landscape of transplant rejection management is undergoing several parallel transformations that together are redefining standards of care. One primary shift is the maturation of precision diagnostics: blood-based assays, advanced imaging modalities, and refined tissue biopsy techniques are converging to enable earlier and more specific detection of immune-mediated injury. These diagnostic advances are complemented by improvements in immunomodulatory medications, including refined antibody therapies, targeted antimetabolites, optimized calcineurin inhibitor regimens, and steroid minimization strategies, creating opportunities for more individualized immunosuppression that reduces both rejection and long-term toxicity.

Alongside clinical innovations, digital health and data integration are changing how monitoring and decision-making occur. Remote patient monitoring, algorithmic risk stratification, and interoperable electronic health records are facilitating more proactive care and tighter coordination among transplant centers, specialty clinics, and research institutes. Regulatory and reimbursement environments are also shifting their focus toward evidence of clinical utility and cost-effectiveness, which incentivizes the development of diagnostics and therapeutics that demonstrate clear impact on outcomes. Finally, partnerships across industry, academic centers, and clinical networks are accelerating translational research and multicenter validation of novel tools. Taken together, these transformative shifts are producing a more responsive, evidence-driven approach to preventing and managing acute, chronic, and hyperacute rejection across organ types.

Assessing how United States tariff changes beginning in 2025 are reshaping procurement, manufacturing footprints, international collaborations, and supply chain resilience for transplant care

The introduction of tariffs in the United States beginning in 2025 has compounded preexisting supply chain pressures and prompted a reevaluation of procurement strategies for many stakeholders involved in transplantation care. Devices and reagents used in blood tests, imaging platforms, and tissue biopsy processing often rely on multinational supply chains; increased import costs and customs complexity have therefore influenced sourcing decisions, inventory practices, and supplier diversification. As a result, some transplant centers and specialty clinics have accelerated efforts to localize critical inventories, negotiate multi-year supplier agreements, or adopt alternative technologies with more domestically available components.

In addition to procurement adaptations, tariffs have affected collaborative dynamics with international research partners and manufacturers. Cross-border clinical trials and technology transfer arrangements have required greater attention to total landed cost, regulatory alignment, and contingency planning. Manufacturers and distributors have responded by reassessing manufacturing footprints, increasing redundancy in critical nodes of the supply chain, and prioritizing transparency in lead times and component provenance. While these adjustments have the potential to increase resilience, they also introduce transitional operational costs and require closer coordination between hospitals, transplant centers, and research institutes to maintain uninterrupted access to diagnostics and therapies. Ultimately, the cumulative impact of tariffs has underscored the need for strategic procurement, robust supplier relationships, and operational flexibility across the transplantation ecosystem.

Segment-driven insights synthesizing rejection phenotypes, diagnostic modalities, therapeutic classes, organ-specific considerations, and care setting influences to guide strategic prioritization

A nuanced understanding of market dynamics emerges by examining the key segments that define transplant rejection management. When viewing the field through the lens of rejection type, acute rejection demands rapid diagnostic clarity and responsive immunosuppression, chronic rejection requires long-term monitoring and strategies to mitigate progressive graft deterioration, and hyperacute rejection necessitates immediate perioperative recognition and intervention. Each rejection phenotype thus imposes distinct clinical priorities and technology requirements.

From the perspective of offerings, diagnostics and testing solutions encompass blood tests that permit noninvasive surveillance, imaging tests that characterize structural and perfusion changes, and tissue biopsy procedures that provide histopathologic confirmation; medications include antibody agents that modulate humoral responses, antimetabolites that interfere with lymphocyte proliferation, calcineurin inhibitors that suppress T-cell activity, and steroids used for both induction and rescue therapy. These categories interact differently across organ types: heart, kidney, liver, lung, and pancreas transplantation each present unique immunologic profiles and clinical surveillance needs that influence the choice and sequencing of diagnostics and therapeutics. Finally, end-user settings such as hospitals and transplant centers deliver comprehensive perioperative and long-term care, research institutes drive translational innovation and validation studies, and specialty clinics often support outpatient monitoring and medication optimization. An integrated view of these segmentations clarifies where clinical unmet needs intersect with technological capabilities and operational realities, enabling stakeholders to prioritize investment, development, and implementation strategies that align with organ-specific and care-setting requirements.

Regional patterns and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine research focus, clinical integration, and access to transplant innovations

Regional variation profoundly affects how innovations in transplant rejection prevention and management are adopted and integrated into care. In the Americas, high-volume transplant centers and established reimbursement pathways often support rapid uptake of advanced diagnostics and novel therapeutics, while regional disparities in access require targeted initiatives to expand capacity and equitable care. Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and health system models; as a result, adoption tends to be uneven, with academic centers and national reference hospitals leading in clinical research and the diffusion of best practices, while other areas focus on pragmatic, resource-efficient approaches.

Across Asia-Pacific, rising transplant volumes and substantial investments in biotechnology and diagnostics have spurred local innovation and manufacturing, contributing to an expanding pipeline of regionally developed tools. However, differences in population demographics, disease etiologies, and care infrastructure mean that clinical pathways and monitoring strategies are often adapted to local contexts. These geographic distinctions also influence collaborative research priorities, the design of multicenter studies, and the scalability of solutions, underscoring the importance of tailoring implementation plans and commercialization strategies to regional strengths, regulatory expectations, and health system realities.

Competitive and collaborative company insights revealing how diagnostics innovators, therapeutic developers, and supply chain strategists are positioning to capture clinical and operational leadership

The competitive landscape in transplant rejection management is characterized by a mix of established healthcare companies and specialized innovators that together drive technological progress and clinical adoption. Diagnostic firms are investing in high-sensitivity blood-based assays and scalable platforms for tissue analysis, while imaging vendors focus on modalities that enhance graft surveillance and functional assessment. Pharmaceutical and biotech companies continue to refine immunosuppressive regimens and advance antibody and small-molecule programs that target specific immune pathways, often collaborating with academic centers to validate clinical endpoints and safety profiles.

Strategic partnerships, co-development agreements, and licensing arrangements are common as organizations seek to combine diagnostic precision with therapeutic innovation. In addition, manufacturers are responding to supply chain pressures by diversifying supplier networks and exploring near-shore manufacturing to reduce vulnerability to international disruptions. Overall, the market exhibits a pragmatic balance between competition and collaboration: firms that demonstrate interoperability with clinical workflows, robust evidence of clinical utility, and reliable supply chains are best positioned to form durable relationships with hospitals, transplant centers, and research institutes.

Actionable recommendations for senior executives and clinical leaders to accelerate diagnostic adoption, strengthen supply chains, align partnerships, and expand equitable access across care settings

Industry leaders should pursue a set of coordinated actions to translate scientific advances into measurable improvements in graft longevity and patient outcomes. First, prioritizing investments in diagnostics that enable earlier, noninvasive detection will improve clinical responsiveness and reduce reliance on more invasive procedures. Secondly, embedding diagnostic-to-therapy algorithms into clinical workflows-supported by interoperable health IT, decision support, and clinician training-will accelerate adoption and improve consistency of care across hospitals, transplant centers, and specialty clinics. Moreover, organizations should pursue strategic partnerships that unite diagnostic makers, pharmaceutical developers, and research institutes to co-design validation studies and real-world evidence programs that demonstrate clinical utility across heart, kidney, liver, lung, and pancreas transplantation.

From an operational perspective, supply chain diversification and transparent supplier relationships are essential to mitigate the downstream effects of trade policies and component shortages. Leaders must also focus on equitable access strategies that address geographic disparities and support capacity building where adoption lags. Finally, corporate and clinical stakeholders should invest in post-market surveillance and longitudinal registries to better understand patterns of acute, chronic, and hyperacute rejection and to refine therapeutic strategies over time. Taken together, these actions will help organizations reduce clinical variability, optimize resource utilization, and expand patient access to state-of-the-art monitoring and treatment.

Transparent mixed-methods research approach integrating peer-reviewed evidence, primary expert interviews, and operational validation to ensure robust and actionable conclusions

The analysis underpinning this report combines a rigorous, mixed-methods research approach designed to ensure credibility, relevance, and practical utility. Secondary research included a systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available technical documentation to characterize diagnostic technologies, therapeutic mechanisms, and clinical management strategies for different rejection phenotypes. This evidence base was supplemented by primary research consisting of structured interviews with transplant clinicians, laboratory directors, procurement officers, and industry executives to capture frontline perspectives on unmet needs, implementation barriers, and practical adoption drivers.

Qualitative findings were validated through expert workshops and cross-checked against operational indicators reported by transplant centers and specialty clinics. Where appropriate, sensitivity analyses and scenario planning were used to explore the effects of supply chain disruptions and policy changes on procurement and clinical continuity. Throughout, quality controls included source triangulation, transparency in assumptions, and iterative review by clinical subject-matter experts to ensure that conclusions reflect current practice and emerging trends in diagnostics, therapeutics, and care delivery.

Conclusion synthesizing clinical and strategic imperatives for improving graft longevity through diagnostics, therapeutics, collaboration, and resilient implementation strategies

Solid organ transplantation sits at a crossroads where scientific innovation, clinical practice, and system-level considerations converge to shape patient outcomes. Advances in diagnostics and therapeutics offer real potential to reduce the incidence and impact of acute, chronic, and hyperacute rejection, yet realizing that potential requires coordinated action across manufacturers, clinicians, health systems, and policymakers. Strategic investments in noninvasive monitoring, evidence generation, interoperable workflows, and resilient supply chains are central to translating scientific progress into routine clinical benefit.

In conclusion, stakeholders that align product development with clinical workflows, prioritize real-world validation, and invest in regional implementation strategies will be best positioned to improve graft survival and patient quality of life. Continued collaboration between hospitals and transplant centers, research institutes, and specialty clinics will drive the next wave of innovation and ensure that technological advances deliver measurable clinical value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Development of donor-specific biomarkers for early detection of allograft rejection
• 5.2. Implementation of machine learning algorithms to predict rejection risk based on patient clinical data
• 5.3. Use of regulatory T cell therapies to induce immune tolerance in solid organ transplant recipients
• 5.4. Exploration of novel costimulation blockade agents to prevent acute graft rejection episodes
• 5.5. Advances in noninvasive imaging techniques for comprehensive post-transplant organ health monitoring
• 5.6. Adoption of personalized immunosuppression regimens guided by pharmacogenomic profiling for transplant patients
• 5.7. Integration of artificial intelligence tools into transplant immunology research to optimize long-term graft survival

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Organ Transplantation Rejection Market, by Rejection Type

• 8.1. Acute Rejection
• 8.2. Chronic Rejection
• 8.3. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by Offering

• 9.1. Diagnosis & Testing Solutions
  • 9.1.1. Blood Tests
  • 9.1.2. Imaging Tests
  • 9.1.3. Tissue Biopsy
• 9.2. Medications
  • 9.2.1. Antibodies
  • 9.2.2. Antimetabolites
  • 9.2.3. Calcineurin Inhibitors
  • 9.2.4. Steroids

10. Solid Organ Transplantation Rejection Market, by Type Of Organ Transplant

• 10.1. Heart
• 10.2. Kidney
• 10.3. Liver
• 10.4. Lung
• 10.5. Pancreas

11. Solid Organ Transplantation Rejection Market, by End User

• 11.1. Hospitals & Transplant Centers
• 11.2. Research Institutes
• 11.3. Specialty Clinics

12. Solid Organ Transplantation Rejection Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Solid Organ Transplantation Rejection Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Solid Organ Transplantation Rejection Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Abbott Laboratories
  • 15.3.2. Accord Healthcare Limited
  • 15.3.3. Asahi Kasei Corporation
  • 15.3.4. Astellas Pharma Inc.
  • 15.3.5. Biocon
  • 15.3.6. Cipla Ltd.
  • 15.3.7. Dr. Reddy's Laboratories Ltd.
  • 15.3.8. Eurofins Transplant Diagnostics
  • 15.3.9. F. Hoffmann-La Roche Ltd.
  • 15.3.10. GlaxoSmithKline PLC
  • 15.3.11. Globela Pharma
  • 15.3.12. Lupin Limited
  • 15.3.13. Manus Aktteva Biopharma LLP
  • 15.3.14. Natco Pharma Ltd.
  • 15.3.15. Novartis AG
  • 15.3.16. Panacea Biotec Pharma Ltd.
  • 15.3.17. Pfizer Inc.
  • 15.3.18. Plexision
  • 15.3.19. Sanofi S.A.
  • 15.3.20. Strides Pharma Global Pte Ltd.
  • 15.3.21. Thermo Fisher Scientific Inc.
  • 15.3.22. Veloxis Pharmaceuticals A/S
  • 15.3.23. Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. SOLID ORGAN TRANSPLANTATION REJECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 140. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 141. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 143. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 145. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 153. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 156. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 157. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 158. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 159. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 160. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 161. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 162. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 170. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 171. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 172. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 173. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 174. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 175. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 176. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 177. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 178. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 212. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 213. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 214. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 215. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 216. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 217. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 218. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 219. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 220. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 221. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 223. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 226. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 227. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 228. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 229. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 230. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 231. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 232. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 233. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 234. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 235. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 240. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 241. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 242. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 243. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 244. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 245. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 246. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 247. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 248. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 249. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 256. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 257. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 258. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 259. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 260. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 261. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 262. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 263. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2018-2024 (USD MILLION)
• TABLE 264. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPLANT, 2025-2032 (USD MILLION)
• TABLE 265. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2024 (USD MILLION)
• TABLE 270. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025-2032 (USD MILLION)
• TABLE 271. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 272. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 273. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2024 (USD MILLION)
• TABLE 274. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2025-2032 (USD MILLION)
• TABLE 275. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 276. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
• TABLE 277. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TYPE OF ORGAN TRANSPL